Best Life Sciences Companies in Oklahoma City, United States
The 41 best Life Sciences companies in Oklahoma City, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Tetherex Pharmaceuticals.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Oklahoma City
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Tetherex Pharmaceuticals Developing novel therapeutics for inflammatory, infectious diseases, and cancer | $55M | 100 mo ago | Series B | 8 | 2014 | — | — | — |
| 2 | Selexys Pharmaceuticals Develops drugs to treat inflammatory and thrombotic diseases | $52M | 138 mo ago | Acquired | 7 | 2002 | — | — | — |
| 3 | Inoveon Services to detect eye diseases including diabetic retinopathy | $16M | 289 mo ago | Acqui-Hired | 10 | 1998 | P. Lloyd Hildebrand Co-Founder | — | — |
| 4 | Progentec Diagnostics Non-invasive diagnostics for therapeutic areas with unmet need | $9M | 16 mo ago | Series A | 14 | 2014 | — | 22 patents AI-driven biomarkers and prognostic tools for autoimmune disease monitoring and flare prediction | — |
| 5 | VADovations Developer of cardiac assist implants | $7M | 78 mo ago | Series A | 12 | 2009 | James Long Founder & CEO | 58 patents Implantable circulatory support devices and tissue‑interface technologies for cardiac assistance | — |
| 6 | Moat Biotechnology Developer of oral vaccines for the treatment of infectious diseases | $6M | 38 mo ago | Series A | — | — | Scott Rollins CEO | — | — |
| 7 | Moleculera Labs Diagnostic panels for infection-associated autoimmune diseases. | $4M | 31 mo ago | Seed | 14 | 2011 | Craig Shimasaki Co-Founder & CEO | 4 patents Immunodiagnostic assays for pediatric neuropsychiatric disorders (PANS/PANDAS) | — |
| 8 | Otologic Pharmaceutics US-based, clinical stage biopharma developing small molecule formulation for Noise-induced hearing loss (NIHL) | $4M | 149 mo ago | Deadpooled | — | 2009 | Richard Kopke Co-Founder | 6 patents Pharmaceutical formulations of N‑acetylcysteine for otic and mucosal drug delivery | — |
| 9 | Pamlico BioPharma Human monoclonal antibodies (hmAbs) for infectious diseases | $3M | 136 mo ago | Deadpooled | 3 | 2013 | — | — | — |
| 10 | Linear Health Sciences Medical device company improving patient safety with breakaway safety valve technology | $3M | 104 mo ago | Seed | 6 | 2015 | — | — | 1 launch |
| 11 | Cadenza Developer of small molecule compounds for demyelinating and inflammatory diseases | $2M | 32 mo ago | Seed | — | 2022 | Carol Curtis Co-Founder & CEO | — | — |
| 12 | Biolytx Developing antimicrobial peptide drugs to combat antibiotic resistance and hospital-acquired infections | $2M | 59 mo ago | Series A | 2 | 2005 | Anne Pereira Co-Founder | — | — |
| 13 | DermaMedics Topical therapeutics for dermatology such as skin pigmentation problems, skin inflammation and others. | $2M | 175 mo ago | Seed | 6 | 2009 | Bryan Fuller Founder & CEO | 10 patents Topical pharmaceutical compositions for treating skin diseases and hyperpigmentation. | — |
| 14 | Levate Manufacturer of smart wheelchairs for orthopedically disabled people | $1M | 66 mo ago | Funding Raised | 2 | 2004 | — | 7 patents Design and manufacturing of wheelchair lift mechanisms for accessibility assistance. | — |
| 15 | Sensulin Developing glucose-responsive insulin to revolutionize diabetes treatment and improve lives | $1M | 99 mo ago | Series B | 5 | 2011 | Chris Rhodes Chief Technology Officer and Co-Founder | 15 patents Vesicle-based pharmaceutical compositions for targeted drug delivery and formulation. | — |
| 16 | SensiQ Technologies SPR-based analytical platforms | $1M | 158 mo ago | Funding Raised | 20 | 2003 | — | — | — |
| 17 | Jortan Pharmaceuticals Aspartic protease inhibitors as therapy for diabetes | $592K | 131 mo ago | Deadpooled | — | 2013 | Clayton I Duncan Chairman & CEO | — | — |
| 18 | COARE Biotechnology Strategic shooter game with millions of players worldwide | $220K | 156 mo ago | Deadpooled | — | 2010 | Eddie Bannerman-Menson Founder & VP | — | — |
| 19 | Haus Bioceuticals Developer of medicines from plants | $150K | 174 mo ago | Seed | 9 | 2009 | Philip Alex Co-Founder & Chief Medical Officer | 39 patents Herbal and curcumin‑peptide antiviral therapeutic formulations | — |
| 20 | Martin Bionics Developer of adjustable open sockets for prosthetics | $100K | 86 mo ago | Seed | 28 | 2005 | Blake Gudgel CEO | — | 1 partnership |
Top 12 Life Sciences companies in Oklahoma City
#1
Series A · Oklahoma City, Oklahoma · founded 2014 · 14 employees$8.8Mraised▾
Progentec Diagnostics develops non-invasive diagnostics for therapeutic areas with unmet need. Its lead program, in collaboration with the Oklahoma Medical Research Foundation, is for the identification of potential disease flare-ups in patients suffering from lupus.
- Apr 2025Grant (prize money)$1.8M
- Jun 2024Grant (prize money)$895.1K
- Jan 2020Series A$5M
- Aug 2019Grant (prize money)$1.7M
#2
Seed · Oklahoma City, Oklahoma · founded 2011 · 14 employees$4.4Mraised▾
Provider of personalized clinical testing services designed to improve the lives of children and adults. The company's services offer advanced testing services to assist physicians in identifying whether an individual's neurological or psychiatric symptoms are caused by autoimmune dysfunction, enabling healthcare providers to treat patients suffering from treatable autoimmune neuropsychiatric disorders.
#3
Series A · Oklahoma City, Oklahoma$6.5Mraised▾
Developer of oral vaccines for the treatment of infectious diseases
#4
Seed · Oklahoma City, Oklahoma · founded 2022$2.4Mraised▾
Developer of small molecule compounds for demyelinating and inflammatory diseases. The company focuses on the development of a series of novel, and highly selective Estrogen Receptor β (ERβ) targeting small-molecule compounds. The company's lead development candidate, CAD-1, for treatment of Multiple Sclerosis (MS).
- Dec 2023Seed$2.4M
#5
Series B · Oklahoma City, Oklahoma · founded 2014 · 8 employees$55.3Mraised▾
Developing novel therapeutics for inflammatory, infectious diseases, and cancer. The company is dedicated to advancing the understanding of inflammation and creating innovative treatments. Focused on helping patients with inflammatory and infectious diseases and cancer, the company develops first-in-class therapeutics targeting cell adhesion proteins. Their lead clinical program features a selectin inhibitor antibody for asthma and chronic obstructive pulmonary disease. The company's pioneering work in molecular mechanisms drives the development of breakthrough therapeutic candidates. They are committed to integrity and excellence in medical research, striving to improve patient lives through scientific advancements.
- Apr 2018Series B$50M
- Oct 2015Series A$4M
- Feb 2015Seed$1.3M
- Sep 2014Grant (prize money)$3.1M
#6
Acquired · Oklahoma City, Oklahoma · founded 2002 · 7 employees$51.6Mraised▾
Selexys Pharmaceuticals (Selexys) develops drugs to treat inflammatory and thrombotic diseases. Its lead product is an antibody (SelG1) is currently under development in a Phase II clinical study for sickle cell disease. Selexys is also developing an antibody for the treatment of Crohn's disease, multiple myeloma, and other inflammatory disorders. In September 2012, Selexys entered into an agreement with Novartis Pharmaceuticals whereby Novartis was granted an exclusive option to acquire Selexys and its lead asset (for $665M) following the successful completion of a Phase 2 clinical study in patients with sickle cell disease.
- Feb 2015Series A$43.2M
- Nov 2011Series A$5M
- Nov 2010Series A$200K
- Jun 2009Series A$3.4M
#7
Series A · Oklahoma City, Oklahoma · founded 2009 · 12 employees$7Mraised▾
VADovations has developed mechanical circulatory support systems for treating cardiac arrest. The company has developed an implantable hemocompatible pump for minimally-invasive percutaneous and endovascular deployment by cardiothoracic surgeons.
- Feb 2020Series A—
- Nov 2019Series A$5M
- Nov 2015Series A$2M
- Mar 2014Grant (prize money)$3.3M
#8
Acqui-Hired · Oklahoma City, Oklahoma · founded 1998 · 10 employees$16Mraised▾
Provider of solutions to detect, and stage and monitor diseases affecting the eye intended to preserve eyesight. The company's technology system helps in detection, staging, monitoring, and treatment of diabetic retinopathy and macular edema, enabling physicians to provide quality care to patients with eye-related diseases.
#9
Series A · Oklahoma City, Oklahoma · founded 2005 · 2 employees$2.4Mraised▾
Developing antimicrobial peptide drugs to combat antibiotic resistance and hospital-acquired infections. This emerging drug development company confronts the crisis in antibiotic drug resistance by advancing antimicrobial peptide drug candidates. Their core technology focuses on novel antibiotic peptides for treating serious hospital-acquired infections, including those resistant to current antibiotics. The company aims to develop its pipeline of peptides to the point of collaborating with pharmaceutical companies for clinical trials. This biotechnology company is focused on creating therapeutic options for serious pathogens where none currently exist, addressing a critical need in healthcare.
- Sep 2021Grant (prize money)$256.6K
- Nov 2015Series A$1.1M
- Oct 2015Conventional Debt$1.3M
- Nov 2010Grant (prize money)$1.8M
#10
Funding Raised · Oklahoma City, Oklahoma · founded 2004 · 2 employees$1.4Mraised▾
LEVATE is a manufacturer of smart wheelchairs for orthopedically disabled people. It has developed a lightweight manual wheelchair accessory that restores reach and independence, empowering people with the freedom to work, play, and love in their daily life. The lift is quickly attachable and detachable from the wheelchair and raises to eye level or any height in between to increase vision and reach in any environment.
- Mar 2021Grant (prize money)$999.9K
- Jun 2020Grant (prize money)—
- 2019Grant (prize money)$224.9K
- Jun 2019Grant (prize money)$224.9K
#11
Seed · Oklahoma City, Oklahoma · founded 2015 · 6 employees$3Mraised▾
Medical device company improving patient safety with breakaway safety valve technology. The flagship product, a safety release valve, aims to reduce the risk of IV catheter dislodgement, protecting patients and saving hospitals time and resources. The platform technology is designed to improve the healthcare experience for patients, caregivers, and healthcare facilities. It address the critical issue of medical tubing dislodgement, offering a plug-and-play device that completes a continuum of care. The solutions aim to minimize complications, standardize practices, and enhance procedure success in vascular access.
- Dec 2017Seed$1.5M
- Seed$1.2M
#12
Deadpooled · Oklahoma City, Oklahoma · founded 2009$4.1Mraised▾
US-based, clinical stage biopharma developing small molecule formulation for Noise-induced hearing loss (NIHL)
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.